Pharmacokinetic Properties of Cardiovascular Drugs

Part of the Treatment in Clinical Medicine book series (TC MEDICINE)


In the last three decades there has been a great increase in the number of drugs available to treat cardiovascular diseases. Patients have a wide spectrum of clinical presentation and can provide complex management problems. They may require emergency treatment using drugs by a parenteral route or long-term oral therapy during which time many clinical parameters are changing. The therapeutic and toxic effects of drugs depend on the available concentration at the site of action, and in general the drug concentration in plasma or whole blood correlates well with the pharmacological response. The development of sensitive and specific analytical methods to measure drugs in blood and/or urine has greatly enhanced our knowledge of their pharmacokinetic behaviour (Mayer et al. 1980).


Therapeutic Drug Monitoring Cardiac Glycoside Cardiovascular Drug Intermittent Infusion Intrinsic Clearance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Beeley LN (1984) Drug interactions. British National FormularyGoogle Scholar
  2. Drayer DE, Reidenberg M (1977) Clinical consequences of polymorphic drugs. Clin Pharmacol Ther 22: 251–258PubMedGoogle Scholar
  3. Fenster PE, Perrier D (1982) Applications of pharmacokinetic principles to cardiovascular drugs. Med Cones Cardiovasc Dis 57: 91–96Google Scholar
  4. Giardina EGV, Fenster PE, Bigger JT Jr, Mayersohn M, Perrier D, Marcus FI (1980) Efficacy, plasma concentrations and adverse effects of a new sustained release procainamide preparation. Am J Cardiol 46: 855–862PubMedCrossRefGoogle Scholar
  5. Kristensen M, Molholm Hansen J, Kampmann J, Lumholtz B, Siersback Nielson K (1974) Drug elimination and renal function. J Clin Pharmacol 14: 307–308PubMedGoogle Scholar
  6. Lindenbaum J, Mellow MH, Blackstone MO, Butler VP (1971) Variation in biological availability of digoxin from four preparations. N Engl J Med 285: 1344–1347PubMedCrossRefGoogle Scholar
  7. Mayer SE, Melman KL, Gilman KG (1980) General principles. In: Gilman AG, Goodman LS, Gilman A (eds) The pharmacological basis of therapeutics. Macmillan, New York, pp 1–27Google Scholar
  8. Oie S, Tozer TN (1979) Effect of altered plasma protein binding on apparent volume of distribution. J Pharm Sci 68: 1203–1205PubMedCrossRefGoogle Scholar
  9. Wilkinson GR, Shand DG (1975) A physiologic approach to hepatic drug clearance. Clin Pharmacol Ther 18: 337–390Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  1. 1.Royal InfirmaryGlasgowScotland, UK
  2. 2.Stobhill General HospitalGlasgowScotland, UK

Personalised recommendations